Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Wuchter

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Leukemia|May 9, 2020
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Vox Sanguinis|November 15, 2023
International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: SummaryDiva Baggio, Lucy C Fox, Erica M Wood, et al.
Vox Sanguinis|November 15, 2023
International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: ResponsesDiva Baggio, Lucy C Fox, Erica M Wood, et al.
Nature Communications|March 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignanciesQingyu Xu, Alexander Streuer, Johann-Christoph Jann, et al.
Nature|August 3, 2018
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH<sup>mut</sup>-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Nature|November 17, 2017
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Haematologica|November 2, 2023
<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasmsVladimir Riabov, Qingyu Xu, Nanni Schmitt, et al.
Journal of Hematology & Oncology|July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trialMaria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
The Journal of Clinical Investigation|November 3, 2022
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patientsSixten Körper, Beate Grüner, Daniel Zickler, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Leukemia|May 9, 2020
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Vox Sanguinis|November 15, 2023
International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: SummaryDiva Baggio, Lucy C Fox, Erica M Wood, et al.
Vox Sanguinis|November 15, 2023
International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: ResponsesDiva Baggio, Lucy C Fox, Erica M Wood, et al.
Nature Communications|March 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignanciesQingyu Xu, Alexander Streuer, Johann-Christoph Jann, et al.
Nature|August 3, 2018
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH<sup>mut</sup>-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Nature|November 17, 2017
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Haematologica|November 2, 2023
<i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasmsVladimir Riabov, Qingyu Xu, Nanni Schmitt, et al.
Journal of Hematology & Oncology|July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trialMaria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
The Journal of Clinical Investigation|November 3, 2022
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patientsSixten Körper, Beate Grüner, Daniel Zickler, et al.
Pageof 12